US Patent Issued to Antares Pharma on Oct. 27 for "Hematocrit modulation through needle assisted jet injection of testosterone" (Pennsylvania, New Jersey Inventors)

ALEXANDRIA, Va., Oct. 27 -- United States Patent no. 12,773,386, issued on Oct. 27, was assigned to Antares Pharma Inc..

"Hematocrit modulation through needle assisted jet injection of testosterone" was invented by Paul K. Wotton (Newtown, Pa.) and Jonathan Jaffe (Annandale, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted injection device."

The patent was filed on Nov. 1, 2021, under Application No. 17/516,313.

*For further information, including images, charts ...